Navigation Links
A hallmark for the development of testicular tumors found in the aberrant regulation of small non-coding RNA
Date:11/21/2013

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain, have studied the role of a peculiar class of small non-coding RNAs that are mainly expressed in the human male germline. Whereas messenger RNAs transmit the genetic information required for protein synthesis, non-coding RNAs are functional molecules that are never translated into proteins and have important roles in diverse cellular processes. In human spermatozoa, these tiny RNAs are epigenetically regulated (by changes in the genome that do not alter the DNA sequence, such as DNA methylation) and play a critical role in male germline development. Importantly, these RNAs have also been detected in human cancer cells.

In a work published in the January 2014 issue of Epigenetics, which is entirely devoted to "Non-coding RNAs in Epigenetic Regulation," the researchers asked if in their natural functional context (the normal human testis) these small RNAs undergo aberrant epigenetic regulation, compromising their function and contributing to the transformation of cells into testicular tumor cells. The reported data suggest that epigenetic disruption of an entire small non-coding RNA pathway in human testis is indeed a hallmark for the development of testicular tumors.


'/>"/>

Contact: Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience
Source:Eurekalert

Page: 1

Related biology news :

1. Artificial womb unlocks secrets of early embryo development
2. REST is crucial for the timing of brain development
3. Embryonic development protein active in cancer growth
4. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
5. Stomata development in plants unraveled -- a valuable discovery for environmental research
6. Promising developments in early diagnosis and treatment of mesothelioma
7. Europe meets to discuss progress in energy research and development
8. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
9. New genes contributing to autism and related neurodevelopmental disorders uncovered
10. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
11. Navigating the IP Minefield of Human Embryonic Stem Cell Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology: